| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized (from mouse) |
| Target | EGFR |
| Clinical data | |
| Routes of administration | Intravenous |
| ATC code | |
| Pharmacokinetic data | |
| Elimination half-life | 62–304 hours |
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| Chemical and physical data | |
| Formula | C6566H10082N1746O2056S40[1] |
| Molar mass | 147659.45 g·mol−1 |
  (what is this?) (verify) | |
Nimotuzumab (h-R3,[2] BIOMAb EGFR, Biocon, India;[3] TheraCIM, CIMYM Biosciences, Canada; Theraloc, Oncoscience, Europe, CIMAher, Center of Molecular Immunology, Havana, Cuba) is a humanized monoclonal antibody that as of 2014 had orphan status in the US and EU for glioma, and marketing approval in India, China, and other countries for squamous cell carcinomas of the head and neck, and was undergoing several clinical trials.
Like cetuximab, nimotuzumab binds to the epidermal growth factor receptor (EGFR), a signalling protein that normally controls cell division. In some cancers, this receptor is altered to cause uncontrolled cell division, a hallmark of cancer. These monoclonal antibodies block EGFR and stop the uncontrolled cell division.
It has a humanized human-mouse h-R3 heavy chain and a humanized human-mouse h-R3 κ-chain.[1][4]
- ^ a b WHO Drug Information, Vol. 19, No. 4, 2005 Proposed INN List 94, p.333
- ^ Ramakrishnan MS, Eswaraiah A, Crombet T, Piedra P, Saurez G, Iyer H, Arvind AS (2009). "Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin". mAbs. 1 (1): 41–8. doi:10.4161/mabs.1.1.7509. PMC 2715181. PMID 20046573.
- ^ BIOMAb EGFR Archived 2014-05-12 at the Wayback Machine (Biocon, India)
- ^ Merck Index 14th Edition Monograph number 10585.